Sei Investments Co. Acquires 33,508 Shares of Roivant Sciences Ltd. $ROIV

Sei Investments Co. increased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 38.6% in the 1st quarter, HoldingsChannel reports. The firm owned 120,326 shares of the company’s stock after acquiring an additional 33,508 shares during the period. Sei Investments Co.’s holdings in Roivant Sciences were worth $3,333,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ROIV. SBI Securities Co. Ltd. lifted its stake in Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares during the period. Allworth Financial LP lifted its position in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the period. Kestra Advisory Services LLC bought a new position in Roivant Sciences during the fourth quarter worth $47,000. Parallel Advisors LLC boosted its stake in Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after acquiring an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC boosted its stake in Roivant Sciences by 7,614.3% during the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after acquiring an additional 2,665 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on ROIV. Guggenheim lifted their price target on shares of Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Friday. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. Weiss Ratings downgraded Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. HC Wainwright boosted their target price on Roivant Sciences from $34.00 to $41.00 and gave the company a “buy” rating in a research report on Friday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $34.77.

Roivant Sciences Trading Up 3.5%

NASDAQ ROIV opened at $36.34 on Friday. The company has a market cap of $26.14 billion, a P/E ratio of -68.57 and a beta of 1.12. The company has a fifty day simple moving average of $33.13 and a 200 day simple moving average of $29.46. Roivant Sciences Ltd. has a 12-month low of $10.90 and a 12-month high of $37.00.

Insider Buying and Selling at Roivant Sciences

In related news, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the transaction, the director owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. This trade represents a 51.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the transaction, the director owned 13,701,546 shares of the company’s stock, valued at $473,388,414.30. This trade represents a 5.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 2,055,913 shares of company stock valued at $69,639,633. Corporate insiders own 8.80% of the company’s stock.

Key Stories Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Guggenheim raised its price target to $42 from $36 and assigned a “Buy” rating. The revision implies meaningful upside and provides a clear near-term bullish catalyst for Roivant Sciences (ROIV). Benzinga analyst upgrade
• Positive Sentiment: Roivant said it expects to launch brepocitinib for dermatomyositis by the end of September, a milestone that could improve confidence in the company’s commercialization strategy. It also plans to target cutaneous sarcoidosis, with Phase 3 data expected in 2028. Brepocitinib launch and pipeline update
• Positive Sentiment: Roivant’s subsidiary Immunovant reported that IMVT-1402 development remains on schedule across several autoimmune indications, including Graves’ disease and myasthenia gravis. Its cash balance is expected to fund operations through a potential Graves’ disease launch, reducing near-term financing concerns. Immunovant corporate update

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.